Frontlight ResearchEarly access
Melanoma trials in Germany
37 of 48 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleA Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Where
- Muenster, Tuebingen
- Age
- 6 months to 17 years
- People
- 370 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT02332668 · EU 2022-501257-36-00 - Phase 4Active, not recruitingDabrafenib and/or Trametinib Rollover Study
- Where
- Augsburg, Essen, Hamburg, Heidelberg, Mannheim
- Age
- 18 years to 100 years
- People
- 100 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00 - Phase 1Active, not recruitingSTART: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
- Where
- Berlin, Frankfurt am Main, Goettingen, Heidelberg, Tübingen
- Age
- 18 years and over
- People
- 15 worldwide
- Run by
- Valo Therapeutics Oy
See details and how to joinNCT05492682 · EU 2024-517580-23-00 - Phase 2Taking peopleA Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Where
- Hamburg, Heidelberg, Leipzig, Mainz, München, Würzburg
- Age
- 18 years and over
- People
- 254 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07492680 - Phase 3Taking peopleSUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- Where
- Berlin, Bonn, Cologne, Dresden, Erlangen, Essen, Frankfurt Am Main, Hamburg, Heidelberg, Leipzig, Mainz
- Age
- 18 years and over
- People
- 450 worldwide
- Run by
- Immatics US, Inc.
See details and how to joinNCT06743126 · EU 2024-517062-42-00 - Phase 2Not yet taking people in GermanyDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Where
- Frankfurt am Main, Giessen
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00 - Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Frankfurt
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - Phase 1/2Taking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Berlin, Dresden, Heidelberg, Heilbronn, Leipzig, Mainz, Muenster
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - Phase 1/2Taking peopleLong-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
- Where
- Berlin, Cologne, Erlangen, Goettingen, Muenster, Munich, Tuebingen, Wuerzburg
- People
- 40
- Run by
- Miltenyi Biomedicine GmbH
See details and how to joinNCT06508775 · EU 2022-501648-14-00 - Phase 1/2Taking peopleA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Where
- Berlin, Essen, Mainz, München, Tübingen
- Age
- 18 years and over
- People
- 1,438 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07070232 · EU 2024-517261-16-00 - Phase 2/3Taking peopleSafety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
- Where
- Berlin, Buxtehude, Dresden, Erfurt, Erlangen, Gera, Halle (Saale), Hamburg, Kiel, Leipzig, Ludwigshafen Am Rhein, Luebeck, Magdeburg, Mainz, Mannheim, Marburg, Minden, Muenster, Nuremberg, Tuebingen, Wuerzburg
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00 - Phase 2Not yet taking people in GermanyPHOENIX - ECP: Extracorporeal PHotopheresis for immune-related cOlitis and/or hEpatitis in advanced melaNoma with inadequate response to steroId eXposure
- Where
- Berlin, Cologne, Dresden, Essen, Freiburg im Breisgau, Halle (Saale), Luebeck, Mainz, Mannheim, Munich
- Age
- 18 years and over
- People
- 46 worldwide
- Run by
- Therakos Europe Limited
See details and how to join2026-526261-14-00 - Phase 3Taking peopleStudy to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
- Where
- Berlin, Dresden, Hamburg, Lübeck, Munich, Würzburg
- Age
- 18 years to 70 years
- People
- 670 worldwide
- Run by
- Iovance Biotherapeutics, Inc.
See details and how to joinNCT05727904 · EU 2022-503140-41-00 - Phase 2Taking peopleEarly detection of side effects in patients with metastatic melanoma receiving immune checkpoint inhibitor therapy by investigation of the CD8+ immune infiltrate using [89Zr]Zr-Df-IAB22M2C-PET
- Where
- Tuebingen
- Age
- 18 years and over
- People
- 35
- Run by
- Universitaetsklinikum Tuebingen AöR
See details and how to join2024-512219-37-00 - Phase 2Taking peopleNeoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma
- Where
- Berlin
- Age
- 18 years and over
- People
- 19 worldwide
- Run by
- Grupo Español Multidisciplinar de Melanoma
See details and how to joinNCT07057596 · EU 2023-509076-42-00 - Phase 2Taking peopleStudy of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
- Where
- Essen, Freiburg im Breisgau, Kiel, Tuebingen
- Age
- 18 years and over
- People
- 162 worldwide
- Run by
- Philogen S.p.A.
See details and how to joinNCT06284590 · EU 2024-519326-20-00 - No phaseTaking peopleSocial Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support Persons
- Where
- Augsburg, Bayreuth, Berlin, Cologne, Erlangen, Regensburg, Würzburg
- Age
- 18 years and over
- People
- 384
- Run by
- University of Regensburg
See details and how to joinNCT07788729 - No phaseTaking peopleGustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention
- Where
- Augsburg, Erlangen, München, Regensburg, Würzburg
- Age
- 18 years and over
- People
- 198
- Run by
- Wuerzburg University Hospital
See details and how to joinNCT07649681 - Phase 1/2Taking peopleA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Where
- Dresden, Essen, Frankfurt, Ulm, Würzburg
- Age
- 18 years and over
- People
- 1,109 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT04895709 - Phase 1Taking peopleA First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
- Where
- Bochum, Cologne, Marburg, Muenster, Munich, Wuerzburg
- Age
- 18 years and over
- People
- 21
- Run by
- Kupando GmbH
See details and how to joinNCT07600476 · EU 2025-522402-21-00 - No phaseTaking peopleClinical Study on High-fiber Diet and Short-term Fasting in Melanoma Under Immunotherapy With Checkpoint Inhibition
- Where
- Berlin
- Age
- 18 years and over
- People
- 60
- Run by
- Charite University, Berlin, Germany
See details and how to joinNCT07680452 - Phase 3Taking peopleVO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
- Where
- Berlin, Dresden, Erfurt, Essen, Frankfurt Am Main, Hamburg, Heidelberg, Kiel, Mainz, Munich, Tuebingen
- Age
- 12 years and over
- People
- 400 worldwide
- Run by
- Replimune, Inc.
See details and how to joinNCT06264180 · EU 2023-508612-29-00 - No phaseTaking peopleReducing Symptom Burden Through Physical Exercise in Melanoma Patients
- Where
- Essen
- Age
- 18 years and over
- People
- 86
- Run by
- Universität Duisburg-Essen
See details and how to joinNCT06985056 - Phase 3Taking peopleAdjuvant Tebentafusp in High Risk Ocular Melanoma
- Where
- Berlin, Essen, Hamburg, Heidelberg
- Age
- 18 years and over
- People
- 290 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT06246149 · EU 2023-510333-28-00 - Phase 1/2Taking peopleACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- Where
- Berlin, Bonn, Dresden, Hamburg, Heidelberg, Mainz, Munich, Würzburg
- Age
- 18 years and over
- People
- 375 worldwide
- Run by
- Immatics US, Inc.
See details and how to joinNCT03686124